Neko Health Raises $700 Million For US AI Body-Scan Clinics
AI News reported that Neko Health raised $700 million to expand AI body-scan clinics in the United States, starting with New York. The source cited FDA 510(k) clearances for two Neko devices; U.S. pricing, additional clinic locations, false-positive rates and completed peer-reviewed validation for the full screening service remain outside the public record.
$700 million in new Series C funding will take Neko Health's AI body-scan clinic model into the United States, starting with New York, AI News reported.
The preventive-screening company combines medical imaging, blood tests, proprietary sensors and clinician review in a clinic visit built around early health-risk detection.
The report said Lightspeed Venture Partners led the round and O.G. Venture Partners co-led it.
Atomico, General Catalyst and Lakestar returned as investors.
Liberty City Ventures, Positive Sum and BDT & MSD joined as new backers.
Funding Brings Disclosed Capital Above $1 Billion
The report put the company's disclosed capital raised since 2023 at more than $1 billion after the new round.
The outlet reported that earlier fundraising included a $65 million Series A in 2023 and a $260 million round in January 2025.
David Ofer of O.G. Venture Partners is expected to join the board, subject to regulatory approval.
The financing also included investments from Mark Zuckerberg and Priscilla Chan, Maria Sharapova, will.i.am and Thierry Henry.
Existing individual investors include Alexis Ohanian and Zoë Saldaña.
The funding is intended to support clinics in New York and other U.S. cities.
A New York waitlist is open.
Additional U.S. locations and the detailed rollout schedule remain outside the cited public materials.
Neko Health Scan Combines Imaging, Blood Tests And Clinician Review
The company's clinics use body-scan hardware, blood testing, AI analysis and custom medical equipment.
The report said the service screens customers for potential signs of skin cancer, cardiovascular disease and diabetes.
The assessment is described by the company as a 60-minute, non-invasive and radiation-free visit.
The company says the scan contains an electrocardiogram, arterial measurements, body-composition analysis and more than 2,000 high-resolution skin images, with blood samples processed at the clinic so results can be reviewed during the same visit.
Results are discussed in person with a medical professional.
Specialist clinicians, including dermatologists and cardiologists, review findings that require further examination, and the company's privacy notice tells customers to continue seeing their existing clinicians for diagnosis and treatment.
Existing Clinics Give Pricing And Usage Evidence
The company currently operates eight clinics across the UK and Sweden, the report said.
The clinic list includes two sites in Stockholm, one each in Manchester and Birmingham, and four London locations in Marylebone, Spitalfields, Covent Garden and Victoria.
The report listed a UK scan price of £299 and a Sweden price of 2,750 Swedish kronor.
Neko said it has completed 100,000 scans since launching the service in 2023, and more than 350,000 people have registered for a scan or joined waitlists.
Three quarters of customers reserve and prepay for a follow-up scan before leaving the appointment, according to Neko.
Repeat scans allow clinicians to compare measurements and skin images over time; the source record does not establish that annual screening is the correct interval for every age or risk group.
FDA Clearances Cover Devices, Not The Full Service
FDA records show two internally developed devices cleared through the 510(k) pathway in May 2026.
Derma-2 received clearance for adjunctive telethermography, and Spectrum-2 received clearance for tissue-oxygen-saturation measurements used in cardiovascular assessment.
The regulatory scope is limited to those devices and intended uses.
It is not an FDA approval of the full Neko Health Scan as one screening service.
Updated Derma, Echo and Spectrum devices collect more health data and automate additional parts of the scanning workflow, according to the company.
The company plans to deploy the devices across its clinics in the coming months.
US Pricing And Clinical Performance Data Remain Undisclosed
U.S. clinics do not currently participate in health-insurance plans, and the company says most services are not covered by a payer.
Customers are expected to pay directly for the initial assessment.
The public record does not include a completed peer-reviewed study validating the full screening service.
A ClinicalTrials.gov-registered study is evaluating the company's multimodal skin-imaging technology for screening and diagnostic-support applications, with skin cancer and Raynaud's phenomenon, and the trial remains ongoing.
The company said its health-outcome figures covered 1,469 returning customers who had a second scan roughly a year after the first visit.
Blood-pressure, cholesterol and blood-sugar measures improved in that group.
The company characterised the analysis as non-scientific and uncontrolled.
U.S. scan pricing, additional U.S. clinic locations, health-insurance arrangements, false-positive rates and completed peer-reviewed validation for the full screening service remain outside the public record.
Summary version for Medium
Neko Health Raises $700 Million For US AI Body-Scan Clinics
What the announcement means beyond the headline
Quick Summary: AI News reported that Neko Health raised $700 million to expand AI body-scan clinics in the United States, starting with New York. The source cited FDA 510(k) clearances for two Neko devices; U.S.
Funding Brings Disclosed Capital Above $1 Billion
The report put the company's disclosed capital raised since 2023 at more than $1 billion after the new round. The outlet reported that earlier fundraising included a $65 million Series A in 2023 and a $260 million round in January 2025.
Neko Health Scan Combines Imaging, Blood Tests And Clinician Review
The company's clinics use body-scan hardware, blood testing, AI analysis and custom medical equipment.
- Point 1: The central topic is ai, with the announcement framed around concrete operating detail.
- Point 2: The report said the service screens customers for potential signs of skin cancer, cardiovascular disease and diabetes.
The important shift is not the AI label, but the operating boundary it creates for teams.
Existing Clinics Give Pricing And Usage Evidence
The company currently operates eight clinics across the UK and Sweden, the report said. The clinic list includes two sites in Stockholm, one each in Manchester and Birmingham, and four London locations in Marylebone, Spitalfields, Covent Garden and Victoria.
Read the Full Deep Dive
Want to explore the complete technical analysis, enterprise trade-offs, and detailed metrics?
Read the full article originally published at SendTech Times
